Clinical Trials

Recurrence, Small Cell Lung Carcinoma

NCT04638491 2024-06-10

Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients

32 enrolled

Advanced Solid Tumor

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

345 enrolled 34 charts 3 FDA

Advanced Solid Tumors

NCT05285033 2023-01-06

LURBICLIN

Completed

312 enrolled

Small Cell Lung Carcinoma

NCT02566993 2021-10-28

ATLANTIS

Phase 3 Completed

613 enrolled 46 charts

Small Cell Lung Carcinoma

NCT03213301 2021-07-14

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Other solid neoplasmThoracic

42 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT02448537 2021-03-03

A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas

42 enrolled 11 charts

Sarcoma

NCT01525589 2020-09-25

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

111 enrolled 31 charts

Breast

Breast Neoplasms

NCT01831089 2020-04-10

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

BreastGynecologicThoracic

69 enrolled 17 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT02421588 2020-04-03

CORAIL

Phase 3 Completed

442 enrolled 33 charts

Gynecologic

Ovarian Neoplasms

NCT01970540 2020-03-09

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

122 enrolled 19 charts

EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02451007 2019-11-19

Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors

39 enrolled 11 charts

Solid Tumors

NCT01951157 2019-09-24

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

69 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT01980667 2017-01-26

Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors

41 enrolled

Tumor-Agnostic

Neoplasms

NCT02210364 2016-12-14

Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).

81 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01405391 2016-01-15

Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks

GastrointestinalOther solid neoplasm

42 enrolled

Major Advanced Solid Tumors Other Than Colorectal

NCT01314599 2015-11-05

Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Other hematologic neoplasm

45 enrolled

Leukemia

NCT00877474 2015-11-04

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

30 enrolled

ADVANCED SOLID TUMORS

NCT01970553 2015-04-01

Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors